ExclusiGraph – Innovation Navigator

Methodology & Guides

This section distils the core principles from the referenced presentation. It explains how drug and biologic approvals, patent listings and regulatory exclusivities interact to determine market entry timing. Use it as a guide while performing calculations in the other tabs.

Drugs & The Orange Book

• New Drug Application (NDA): identifies Orange Book listable patents (composition, formulation, method of use). The applicant must list patents within 30 days of approval or issuance.
• Generic pathways: abbreviated new drug applications (ANDAs) and 505(b)(2) applications rely on innovator safety/efficacy data. Applicants certify against each listed patent via Paragraph I (no patent), II (expired), III (expiry date), IV (invalid/not infringed) or via a Section viii statement for carved-out uses.
• Paragraph IV & 30‑month stay: filing a Paragraph IV certification constitutes an act of infringement. Innovators have 45 days to sue; doing so triggers a stay of FDA approval for the longer of 30 months from certification or 7½ years from NCE approval, unless the case is decided sooner.
• 180‑day generic exclusivity: the first ANDA filer with a Paragraph IV certification may obtain 180 days of market exclusivity; subsequent applicants cannot be approved until this period expires.

Biologics & The Purple Book

• Biosimilar pathway (aBLA): applicants must demonstrate high similarity to the reference product and may elect to participate in the “patent dance” to exchange confidential information and resolve patent disputes.
• Reference product exclusivity: a biosimilar or interchangeable biologic cannot be approved until 12 years after the reference product’s first license. An aBLA may not be filed until year 4. Supplemental BLAs and changes not altering the molecular structure are not eligible for new exclusivity.
• Orphan and pediatric biologic exclusivities: biologics treating diseases affecting fewer than 200 000 U.S. patients receive 7‑year orphan exclusivity for the same indication, while completing an FDA‑requested pediatric study adds six months to the end of any existing biologic marketing exclusivity.

Market Exclusivity Types (Drugs)

• New Chemical Entity (NCE): 5‑year bar on ANDA/505(b)(2) approval for drugs with new active moieties. ANDA/505(b)(2) may be filed after year 4 with a Paragraph IV certification, triggering the 30‑month stay.
• Clinical Investigation (CI): 3‑year exclusivity for applications containing new clinical investigations necessary for approval (e.g., new indications or dosage forms). ANDAs may be filed at any time, but approval is blocked during the exclusivity period. Stays under Paragraph IV can run concurrently.
• Orphan drug exclusivity: 7‑year protection against approval of the same active moiety for the same rare disease or condition. Approval is allowed for clinically superior products or different indications.
• Pediatric exclusivity: six‑month extension added to the end of any existing marketing exclusivity or patent term when the sponsor completes an FDA‑requested pediatric study. Applies to all dosage forms and indications of the same active.
• QIDP (Qualified Infectious Disease Product): adds 5 years to the NCE, CI or orphan exclusivity for designated antibiotics and antifungals.

Patent Term Extension (PTE)

• PTE compensates for regulatory delays in drug, biologic or device approvals. Extensions are available only for patents that issued during the regulatory review period and cover the approved product or its use.
• The extension equals one‑half of the time spent in the testing phase (clinical development) plus the entire review phase, minus any period during which the applicant failed to act with due diligence. The result is capped at five years, and the patent term after extension cannot exceed 14 years from the product’s approval.
• Only one patent per product may receive an extension, and the application must be filed within 60 days of FDA approval.

Strategic Considerations

• Secondary patents (e.g., formulations, methods of use) and line‑extension products can provide additional protection but depend on their validity and scope. Regulatory exclusivity is generally more predictable.
• Life‑cycle management begins early: sponsors often introduce improvements or new indications before generic or biosimilar entry to maintain market share.
• Understanding the interplay between patents, exclusivities and litigation is crucial for accurately forecasting generic entry and assessing portfolio risk.

Exclusivity & Extensions

The U.S. regulatory framework provides several exclusivity periods that delay approval of generic or biosimilar competitors. The durations below are approximations based on statutory provisions and may vary with specific circumstances:

Exclusivity Calculator

Select a patent node, choose one or more applicable exclusivity types and enter the regulatory approval date. The tool will stack the durations, compute the total exclusivity period and allow you to add it as an LOE event.